The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...

CDK4/6 inhibitors are targeted drugs that can be used for women with a common type of breast cancer: hormone ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...

A 72-year-old woman with metastatic ER/PR-positive breast cancer who had been on ribociclib and letrozole for 1 year ... The mechanism of injury in CDK 4/6 inhibitor-induced colitis is unknown but may ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

The team first confirmed that three CDK4/6 inhibitors, ribociclib, palbociclib, and abemaciclib, could penetrate the blood brain barrier. Ribociclib, however, had several advantages, including ...

The team first confirmed that three CDK4/6 inhibitors, ribociclib, palbociclib, and abemaciclib, could penetrate the blood brain barrier. Ribociclib, however, had several advantages, including ...